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Calcineurin and osteoporosis
Th e two commonly used immunosuppressant drugs 
cyclosporin A and tacrolimus (FK506) are known to 
signifi cantly deplete calcium in the body, leading to bone 
loss, osteoporosis, and fractures. It has been speculated 
that these drugs use the calcineurin pathway to exert their 
skeletal eff ects, but it has never been proven. In a new study, 
Sun et al. examined whether calcineurin played a role in 
regulating skeletal remodeling. Osteoblasts were found to 
contain mRNA and protein for all isoforms of calcineurin 
A and B. In gain-of-function studies, enhanced expression 
of calcineurin Aα in osteoblasts increased the amounts of 
the diff erentiation markers Rwunx2, alkaline phosphatase, 
bone sialoprotein, and osteocalcin. Th is was associated 
with a dramatic enhancement of bone formation in intact 
calvarial cultures. Also, calcineurin Aα mice displayed severe 
osteoporosis, markedly reduced mineral apposition rates, and 
weakened colony formation in ex vivo stromal-cell cultures. 
Th e latter was associated with signifi cant reductions in Runx2, 
bone sialoprotein, and osteocalcin expression. Th e eff ects 
were paralleled in wild-type cultures in response to FK506. 
Th ese results verify that calcineurin regulates bone formation 
via osteoblast diff erentiation. Th is information could help 
researchers develop immunosuppressant drugs that protect 
the calcineurin pathway in bones. (Proc Natl Acad Sci USA 
2005; 102: 17130–17135).
Juan Oliver
Mycophenolate a first-line therapy 
for severe lupus nephritis?
Th e search continues for less toxic treatment alternatives 
to corticosteroids and cytotoxic drugs for severe lupus 
nephritis. In a 24-week randomized, open-label trial, Ginzler 
et al. compared oral mycophenolate mofetil to intravenous 
cyclophosphamide in 140 patients with lupus nephritis. In this 
study, mycophenolate mofetil was initiated at 1000 mg per day 
and increased to 3000 mg per day as tolerated, and the dose of 
monthly intravenous cyclophosphamide was initiated at 0.5 g 
per m2 of body-surface area, which was increased to 1.0 g per 
m2. Patients were crossed over to the other regimen at 12 weeks 
if there was an inadequate response in renal parameters. In 
the intention-to-treat analysis, 16 of the 71 patients (22.5%) 
receiving mycophenolate mofetil versus 4 of the 69 patients 
receiving cyclophosphamide (5.8%) had complete remission 
(P = 0.005). Partial remission occurred in 21 of the 71 patients 
(29.6%) and 17 of the 69 patients (24.6%), respectively (P = 
0.51). Th ree patients receiving cyclophosphamide died, two 
during protocol therapy. Patients receiving mycophenolate had 
fewer severe infections and hospitalizations but more diarrhea. 
Mycophenolate mofetil appeared to be more eff ective than 
intravenous cyclophosphamide in inducing remission of lupus 
nephritis and had a better safety profi le. (N Engl J Med 2005; 
353: 2219–2228)
Jai Radhakrishnan
Aquaporin 7 deficiency linked to 
obesity
New research has identifi ed a member of the aquaporin family 
as playing a role in obesity. Although aquaporins were fi rst 
discovered as water channels, they also conduct glycerol. 
Hydrolysis of triglycerides in adipocytes (under the control 
of β-adrenergic agonists) results in the release of free fatty 
acids and glycerol. One aquaporin, aquaporin 7 (Aqp7), is 
expressed in adipocytes. Recently, two groups, Hibuse et al. and 
Hara-Chikuma et al., showed that Aqp7 knockout mice had 
adipocytes with large lipid contents. Hibuse et al. also found 
low plasma glycerol levels and impaired glycerol release in 
mice given a β-adrenergic agonist. Remarkably, wild-type and 
knockout mice weighed the same until 10 weeks of age, but 
knockout mice developed adult-onset obesity. Adipocytes of 
knockout mice were larger and accumulated more triglycerides 
compared with wild-type mice. In addition, knockout mice 
developed not only obesity but also insulin resistance aft er 
consumption of a high-fat, high-sucrose diet. Examination 
of white adipose tissue of the knockout mice showed that, at 
a time when their weight was equal to that of the wild-type 
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mice, there was no diff erence in the abundance or function 
of the insulin signaling pathway molecules. Nor was there 
any diff erence in oxygen consumption or in the level of the 
uncoupling protein. However, the glycerol content of the white 
adipose tissue was elevated, and the triglyceride levels became 
rapidly elevated, suggesting re-incorporation of glycerol into 
triglycerides. Glycerol kinase, the fi rst critical enzyme in this 
pathway, was found to be induced both in situ and in vitro. 
Isolated adipocytes from wild-type mice had normal glycerol 
kinase activity, whereas cells whose Aqp7 was knocked down 
by small interfering RNA also increased their kinase activity. 
Th ese results indicate that the disruption of Aqp7 causes obesity 
by increasing adipose glycerol kinase activity and accelerating 
triglyceride synthesis in adipocytes. Th e mechanism by which 
aquaporin disruption causes this induction of glycerol kinase 
is obscure. (Proc Natl Acad Sci USA 2005; 102: 10993–10998; J 
Biol Chem 2005; 280: 15493–15496)
Qais Al-Awqati
Nephritis can cause prionuria
Prion infections are typically restricted to the central nervous 
and lymphatic systems, but a recent study found that chronic 
kidney infl ammation can cause prions to spread to the urine. 
Th e authors propose that because chronic kidney infl ammation 
induces lymphoneogenesis, it facilitates the replication of 
prions. Seeger et al. administered prions to mice with nephritis. 
Th e urinary proteins from the scrapie-infected nephritis 
containing organized infl ammatory foci induced scrapie 
upon inoculation into uninfected mice. However, glomerular 
nephritis lacking lymphofollicular foci was not associated with 
prionuria. Th e authors conclude that urine may be a venue for 
prion transmission, and that kidney disease with infl ammation 
could cause the spread of prions. (Science 2005; 310: 324–326)
Juan Oliver
A new urinary protein prevents 
kidney stones
A relatively small number of proteins that inhibit kidney 
stone formation are known. Identifi cation of additional stone 
inhibitors would be of great interest. Chutipongtanate et al. 
combined conventional biochemical methods with recent 
advances in mass spectrometry to identify a novel calcium 
oxalate (CaOx) crystal growth inhibitor in normal human urine. 
Isolation and separation of urinary anionic proteins identifi ed 
a fraction with potent inhibitory activity against CaOx crystal 
growth. Th e protein with inhibitory activity was identifi ed by 
matrix-assisted laser desorption/ionization–time-of-fl ight mass 
spectrometry and electrospray ionization–quadrupole–time-
of-fl ight tandem mass spectrometry as human trefoil factor 
1 (TFF1). Western blotting confi rmed the identifi cation, and 
functional studies demonstrated that TFF1’s inhibitory potency 
was similar to that of nephrocalcin. Th e activity of urinary 
TFF1 was inhibited by TFF1 antisera, with an anti-C-terminal 
antibody being particularly eff ective. Th e authors propose a 
model in which the four C-terminal glutamic residues of TFF1 
interact with calcium ions to prevent CaOx crystal growth. TFF1 
was signifi cantly less abundant in the urine of patients with 
idiopathic CaOx kidney stones than in that of control subjects. 
Th ese data indicate that TFF1 is a novel, potent CaOx crystal 
growth inhibitor with a potential pathophysiological role in 
nephrolithiasis. (J Clin Invest 2005; 115: 3613–3622) 
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